MCID: GLL017
MIFTS: 42

Gallbladder Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Adenocarcinoma

Aliases & Descriptions for Gallbladder Adenocarcinoma:

Name: Gallbladder Adenocarcinoma 12 14 69
Adenocarcinoma of the Gallbladder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3500
NCIt 47 C9166
UMLS 69 C0279651

Summaries for Gallbladder Adenocarcinoma

Disease Ontology : 12 A gallbladder carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Gallbladder Adenocarcinoma, also known as adenocarcinoma of the gallbladder, is related to gallbladder pleomorphic giant cell adenocarcinoma and adenocarcinoma, and has symptoms including abdominal pain An important gene associated with Gallbladder Adenocarcinoma is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Nanog in Mammalian ESC Pluripotency and ErbB signaling pathway. The drugs Oxaliplatin and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include lymph node and breast, and related phenotypes are Decreased viability with paclitaxel and cellular

Related Diseases for Gallbladder Adenocarcinoma

Diseases related to Gallbladder Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
id Related Disease Score Top Affiliating Genes
1 gallbladder pleomorphic giant cell adenocarcinoma 11.0
2 adenocarcinoma 10.6
3 pineal region mature teratoma 10.3 EGFR ERBB2
4 triple-receptor negative breast cancer 10.2 EGFR ERBB2
5 skin sarcoma 10.2 EGFR ERBB2
6 cervical lymphoepithelioma-like carcinoma 10.2 EGFR ERBB2
7 kunjin encephalitis 10.2 ERBB2 MYB
8 nervous system hibernoma 10.2 EGFR ERBB2
9 ovarian cystadenocarcinoma 10.2 EGFR ERBB2
10 ureter adenocarcinoma 10.2 EGFR MUC2
11 sclerosing hemangioma 10.2 EGFR ERBB2 MUC2
12 spastic diplegia infantile type 10.1 EGFR ERBB2 MUC2
13 his bundle tachycardia 10.1 EGFR ERBB2 MUC2
14 retrograde amnesia 10.1 EGFR ERBB2 MUC2
15 basaloid squamous cell carcinoma 10.1 EGFR ERBB2
16 anomalous left coronary artery from the pulmonary artery 10.1 EGFR ERBB2
17 malignant pleural solitary fibrous tumor 10.1 EGFR ERBB2 MUC2
18 proctitis 10.1 EGFR ERBB2 MUC2
19 combined t cell and b cell immunodeficiency 10.1 EGFR ERBB2
20 pearson syndrome 10.1 EGFR ERBB2 SRC
21 middle ear adenocarcinoma 10.1 EGFR EZH2
22 dysembryoplastic neuroepithelial tumor 10.0 EGFR ERBB2 PSCA
23 bardet-biedl syndrome 10.0 EGFR ERBB2 PSCA
24 placenta praevia 10.0 EGFR ERBB2 PSCA
25 facial dermatosis 9.9 EGFR ERBB2 MUC2 PSCA
26 glycogen storage disease 9.9 EGFR ERBB2 MUC2 PSCA
27 cholecystitis 9.9
28 xanthogranulomatous cholecystitis 9.8
29 ladd syndrome 9.8 EGFR ERBB2 EZH2
30 gastrointestinal stromal tumor 9.6
31 pulmonary hypertension 9.6
32 chronic lymphocytic leukemia 9.6
33 leukemia 9.6
34 ulcerative colitis 9.6
35 gallbladder adenoma 9.6
36 colitis 9.6
37 dermatomyositis 9.6
38 sclerosing cholangitis 9.6
39 gastric adenocarcinoma 9.6
40 adenosquamous carcinoma 9.6
41 adenoma 9.6
42 intestinal obstruction 9.6
43 cholangitis 9.6
44 meningitis 9.6
45 secondary sclerosing cholangitis 9.6
46 basal cell carcinoma 7 9.5 EGFR ERBB2 EZH2 MUC2 PSCA SRC
47 split-hand/foot malformation with long bone deficiency 1 9.4 EGFR ERBB2 EZH2 PSCA SRC TSG101
48 prostate signet ring cell adenocarcinoma 8.6 CCT2 EGFR EPHA7 ERBB2 EZH2 MUC2

Graphical network of the top 20 diseases related to Gallbladder Adenocarcinoma:



Diseases related to Gallbladder Adenocarcinoma

Symptoms & Phenotypes for Gallbladder Adenocarcinoma

UMLS symptoms related to Gallbladder Adenocarcinoma:


abdominal pain

GenomeRNAi Phenotypes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with paclitaxel GR00179-A-1 8.92 EGFR ERBB2 SRC
2 Decreased viability with paclitaxel GR00179-A-3 8.92 EGFR

MGI Mouse Phenotypes related to Gallbladder Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 TSG101 EGFR ERBB2 EZH2 MUC2 MYB
2 embryo MP:0005380 9.87 EGFR ERBB2 EZH2 MYB S1PR1 SRC
3 endocrine/exocrine gland MP:0005379 9.8 EGFR ERBB2 EZH2 MUC2 MYB SRC
4 integument MP:0010771 9.63 EGFR ERBB2 EZH2 MYB SRC TSG101
5 neoplasm MP:0002006 9.5 TSG101 EGFR ERBB2 EZH2 MUC2 PSCA
6 normal MP:0002873 9.17 EGFR ERBB2 EZH2 MYB PSCA S1PR1

Drugs & Therapeutics for Gallbladder Adenocarcinoma

Drugs for Gallbladder Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 154)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
6 Anesthetics Phase 4,Phase 3
7 Anesthetics, General Phase 4,Phase 3
8 Central Nervous System Depressants Phase 4,Phase 3
9 Anesthetics, Inhalation Phase 4
10 Platelet Aggregation Inhibitors Phase 4
11 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
12
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
13
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
14
Trioxsalen Approved Phase 3 3902-71-4 5585
15
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
18
Ondansetron Approved Phase 3 99614-02-5 4595
19
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
20
Levoleucovorin Approved Phase 3,Phase 1,Phase 2 68538-85-2
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
22
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 54575, 6560146 143
23 Antimetabolites Phase 3,Phase 2,Phase 1
24 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1
26 Antiviral Agents Phase 3,Phase 2,Phase 1
27 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
28 Dermatologic Agents Phase 3,Phase 2
29 Dihematoporphyrin Ether Phase 3
30 Ether Phase 3
31 Photosensitizing Agents Phase 3
32 Adjuvants, Anesthesia Phase 3
33 Analgesics Phase 3
34 Analgesics, Opioid Phase 3
35 Anesthetics, Intravenous Phase 3
36 Narcotics Phase 3
37 pancreatic polypeptide Phase 3,Phase 2,Phase 1
38 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
39 Anti-Anxiety Agents Phase 3
40 Antiemetics Phase 3
41 Anti-Inflammatory Agents Phase 3
42 Antineoplastic Agents, Hormonal Phase 3
43 Antipruritics Phase 3
44 Antipsychotic Agents Phase 3
45 Autonomic Agents Phase 3
46 BB 1101 Phase 3
47 Dexamethasone 21-phosphate Phase 3
48 Dexamethasone acetate Phase 3 1177-87-3
49 Gastrointestinal Agents Phase 3
50 glucocorticoids Phase 3

Interventional clinical trials:

(show top 50) (show all 113)
id Name Status NCT ID Phase
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4
2 Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery Recruiting NCT02174575 Phase 4
3 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3
4 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3
5 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3
6 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3
7 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
8 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3
9 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
10 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3
11 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3
12 Study of GEMOX(Gemcitabine/Oxaliplatin) Versus XELOX(Xeloda/Oxaliplatin) in Advanced Biliary Tract Carcinoma Recruiting NCT01470443 Phase 3
13 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Recruiting NCT01926236 Phase 3
14 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3
15 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3
16 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Unknown status NCT00142480 Phase 2
17 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
18 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2
19 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2
20 A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC Completed NCT01267344 Phase 2
21 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2
22 Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder Completed NCT00085410 Phase 2
23 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
24 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2
25 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2
26 Adjuvant Palliative Capecitabine and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Biliary Tract Cancer Completed NCT00073905 Phase 2
27 Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer Completed NCT00096083 Phase 2
28 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2
29 Avastin and Tarceva for Upper Gastrointestinal Cancers Completed NCT00350753 Phase 2
30 Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma Completed NCT01389414 Phase 2
31 Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2
32 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2
33 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed NCT00338988 Phase 2
34 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Completed NCT00660699 Phase 2
35 Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2
36 Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Completed NCT00033462 Phase 2
37 DX-8951f in Treating Patients With Biliary Cancer Completed NCT00005938 Phase 2
38 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2
39 A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer Completed NCT00955721 Phase 1, Phase 2
40 Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture Completed NCT01320241 Phase 2
41 Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery Completed NCT00101036 Phase 2
42 Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary Tumors Completed NCT00356889 Phase 2
43 MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery Completed NCT01425879 Phase 2
44 Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer Completed NCT00903396 Phase 2
45 Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer Completed NCT00107536 Phase 2
46 A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Recruiting NCT02053376 Phase 2
47 Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Recruiting NCT02333188 Phase 1, Phase 2
48 Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma Recruiting NCT02836847 Phase 2
49 Pilot Study of Percutaneous Irreversible Electroporation to Treat Unresectable Hepatic Carcinoma Close to the Gallbladder Recruiting NCT02332551 Phase 1, Phase 2
50 Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tree Cancer Recruiting NCT01855724 Phase 2

Search NIH Clinical Center for Gallbladder Adenocarcinoma

Genetic Tests for Gallbladder Adenocarcinoma

Anatomical Context for Gallbladder Adenocarcinoma

MalaCards organs/tissues related to Gallbladder Adenocarcinoma:

39
Lymph Node, Breast

Publications for Gallbladder Adenocarcinoma

Articles related to Gallbladder Adenocarcinoma:

(show top 50) (show all 85)
id Title Authors Year
1
Diffusion-weighted magnetic resonance imaging of gallbladder adenocarcinoma: analysis with emphasis on histologic grade. ( 27133665 )
2016
2
Cytokeratin 17 Expression is Associated With Poor Prognosis in Gallbladder Adenocarcinoma. ( 26990743 )
2016
3
Immunohistochemical expression of mucin antigens in gallbladder adenocarcinoma: MUC1-positive and MUC2-negative expression Is associated with vessel invasion and shortened survival. ( 27672051 )
2016
4
Breast metastasis from recurrent gallbladder adenocarcinoma: a case report with review of the literature. ( 27512606 )
2016
5
Gallbladder adenocarcinoma and paraneoplastic parathyroid hormone mediated hypercalcemia. ( 27081650 )
2016
6
BRMS1 and HPA as Progression, Clinical Biological Behaviors, and Poor Prognosis-related Biomarkers for Gallbladder Adenocarcinoma. ( 26200836 )
2015
7
Surgical resection of solid gallbladder adenocarcinoma presenting as a large mass: report of a case. ( 25884804 )
2015
8
Gallbladder neuroendocrine carcinoma: report of 10 cases and comparision of clinicopathologic features with gallbladder adenocarcinoma. ( 26339390 )
2015
9
18F-FDG PET/CT Imaging of Gallbladder Adenocarcinoma - A Pictorial Review. ( 26430572 )
2015
10
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naA^ve pT2 gallbladder adenocarcinoma patients. ( 26266900 )
2015
11
Dermatomyositis as the first manifestation of gallbladder adenocarcinoma: case report and literature overview. ( 25890241 )
2015
12
Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma. ( 26176038 )
2014
13
Vitamin D receptor genetic variants are associated with susceptibility of gallbladder adenocarcinoma in a Chinese cohort. ( 25078595 )
2014
14
Re: metastasis of gallbladder adenocarcinoma to Bauhin's valve: an extremely rare cause of intestinal obstruction. ( 25246829 )
2014
15
Gallbladder adenocarcinoma with sarcoid-like reaction in regional lymph nodes: report of a case. ( 25495692 )
2014
16
Overexpression of MTA1 and loss of KAI-1 and KiSS-1 expressions are associated with invasion, metastasis, and poor-prognosis of gallbladder adenocarcinoma. ( 25688501 )
2014
17
Histological phenotype is correlated with the wall-invasion pattern of gallbladder adenocarcinoma. ( 25355436 )
2014
18
Lymph node status after resection for gallbladder adenocarcinoma: Prognostic implications of different nodal staging/scoring systems. ( 25312786 )
2014
19
Expression of Cell Cycle-Related Proteins, p16, p53 and p63 as Important Prognostic Markers in Gallbladder Adenocarcinoma. ( 24178677 )
2013
20
Clinicopathological features and CCT2 and PDIA2 expression in gallbladder squamous/adenosquamous carcinoma and gallbladder adenocarcinoma. ( 23782473 )
2013
21
PSCA and Oct-4 expression in the benign and malignant lesions of gallbladder: implication for carcinogenesis, progression, and prognosis of gallbladder adenocarcinoma. ( 23984394 )
2013
22
Correlation of S1P1 and ERp29 expression to progression, metastasis, and poor prognosis of gallbladder adenocarcinoma. ( 23558074 )
2013
23
Expression of p53 upregulated modulator of apoptosis (PUMA) and C-myb in gallbladder adenocarcinoma and their pathological significance. ( 23475628 )
2013
24
Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: A propensity score-matched Surveillance, Epidemiology, and End Results analysis. ( 23876364 )
2013
25
Cheek metastasis from gallbladder adenocarcinoma. ( 23669176 )
2013
26
Immunohistochemical expression of phospho-mTOR is associated with poor prognosis in patients with gallbladder adenocarcinoma. ( 23544944 )
2013
27
MTDH and EphA7 are markers for metastasis and poor prognosis of gallbladder adenocarcinoma. ( 21964981 )
2013
28
Gastrointestinal Stromal Tumor with Synchronous Gallbladder Adenocarcinoma. ( 23749654 )
2013
29
Coexistence of xanthogranulomatous cholecystitis and gallbladder adenocarcinoma: a fortuitous association? ( 24471194 )
2013
30
Antiproliferative and apoptosis-inducing activity of curcumin against human gallbladder adenocarcinoma cells. ( 23645731 )
2013
31
Secondary Sclerosing Cholangitis due to Gallbladder Adenocarcinoma. ( 23626514 )
2013
32
Cutaneous metastasis of gallbladder adenocarcinoma in a patient with chronic lymphocytic leukemia: a case report and review of the literature. ( 23467457 )
2013
33
Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma. ( 22076922 )
2012
34
Gallbladder adenocarcinoma: evaluation of the prognostic factors in 100 resectable cases in Brazil. ( 22569972 )
2012
35
Up-regulation of galectin-3 and Sambucus nigra agglutinin binding site is associated with invasion, metastasis and poor-progression of the gallbladder adenocarcinoma. ( 22497866 )
2012
36
Expression of MUC1 and MUC4 in gallbladder adenocarcinoma. ( 23136569 )
2012
37
Frequency of genetic alterations observed in cell cycle regulatory proteins and microsatellite instability in gallbladder adenocarcinoma: a translational perspective. ( 21545232 )
2011
38
Gallbladder adenocarcinoma with extended intramural spread in adenomyomatosis of the gallbladder with the pearl necklace sign. ( 21375832 )
2011
39
Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. ( 21307665 )
2011
40
Identification of PEG10 and TSG101 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. ( 21455631 )
2011
41
Ala499Val (C>T) and Lys939Gln (A>C) polymorphisms of the XPC gene: their correlation with the risk of primary gallbladder adenocarcinoma--a case-control study in China. ( 21113018 )
2011
42
Overexpression of EZH2 and loss of expression of PTEN is associated with invasion, metastasis, and poor progression of gallbladder adenocarcinoma. ( 21719208 )
2011
43
Giant gallbladder: adenocarcinoma complicated with empyema. ( 21217498 )
2011
44
Metastatic gallbladder adenocarcinoma with signet-ring cells: A case report. ( 21917161 )
2011
45
National trends in the management and survival of surgically managed gallbladder adenocarcinoma over 15 years: a population-based analysis. ( 20824371 )
2010
46
Invasive micropapillary variant of the gallbladder adenocarcinoma and its aggressive potential for lymph node metastasis. ( 20460736 )
2010
47
Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma. ( 19904536 )
2010
48
Identification of musashi-1 and ALDH1 as carcinogenesis, progression, and poor-prognosis related biomarkers for gallbladder adenocarcinoma. ( 22012766 )
2010
49
Gallbladder adenocarcinoma with human chorionic gonadotropin: a case report and review of literature. ( 20594358 )
2010
50
Stromal laminin-5gamma2 chain expression is associated with the wall-invasion pattern of gallbladder adenocarcinoma. ( 19265264 )
2009

Variations for Gallbladder Adenocarcinoma

Expression for Gallbladder Adenocarcinoma

Search GEO for disease gene expression data for Gallbladder Adenocarcinoma.

Pathways for Gallbladder Adenocarcinoma

Pathways related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.01 EGFR EPHA7 ERBB2 S1PR1 SRC
2
Show member pathways
12.09 EGFR ERBB2 SRC
3 12.07 EGFR ERBB2 SRC
4
Show member pathways
12.06 EGFR ERBB2 SRC
5 11.93 EGFR ERBB2 SRC
6
Show member pathways
11.91 EGFR ERBB2 SRC
7
Show member pathways
11.87 EGFR ERBB2 SRC
8
Show member pathways
11.84 EGFR ERBB2 SRC
9
Show member pathways
11.7 EGFR ERBB2 SRC
10 11.44 EGFR ERBB2 SRC
11 11.4 EGFR ERBB2 SRC
12 11.33 EGFR ERBB2 SRC
13 11.18 EGFR ERBB2 SRC
14 11.14 EGFR SRC
15 11.08 EGFR EPHA7 ERBB2 SRC
16 11.07 EGFR ERBB2
17 11.03 EGFR ERBB2
18 10.99 EGFR ERBB2 SRC
19 10.95 EGFR SRC
20 10.76 EGFR SRC
21 10.69 EGFR SRC
22 10.66 EGFR SRC TSG101

GO Terms for Gallbladder Adenocarcinoma

Cellular components related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 8.8 EGFR ERBB2 TSG101

Biological processes related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 18)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of GTPase activity GO:0043547 9.88 EGFR ERBB2 EZH2 S1PR1
2 negative regulation of transcription, DNA-templated GO:0045892 9.83 EZH2 MYB SRC TSG101
3 protein autophosphorylation GO:0046777 9.69 EGFR ERBB2 SRC
4 positive regulation of protein phosphorylation GO:0001934 9.67 EGFR EPHA7 ERBB2
5 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.63 EGFR EPHA7 ERBB2
6 liver regeneration GO:0097421 9.57 EGFR EZH2
7 negative regulation of epidermal growth factor receptor signaling pathway GO:0042059 9.56 EGFR TSG101
8 peptidyl-tyrosine phosphorylation GO:0018108 9.56 EGFR EPHA7 ERBB2 SRC
9 cellular response to reactive oxygen species GO:0034614 9.55 EGFR SRC
10 regulation of cell motility GO:2000145 9.54 EGFR ERBB2
11 positive regulation of smooth muscle cell proliferation GO:0048661 9.5 EGFR MYB S1PR1
12 regulation of peptidyl-tyrosine phosphorylation GO:0050730 9.48 EGFR EPHA7
13 negative regulation of ERBB signaling pathway GO:1901185 9.43 EGFR ERBB2
14 regulation of cell-cell adhesion GO:0022407 9.4 EPHA7 SRC
15 regulation of bone resorption GO:0045124 9.37 S1PR1 SRC
16 ERBB2 signaling pathway GO:0038128 9.33 EGFR ERBB2 SRC
17 regulation of ERK1 and ERK2 cascade GO:0070372 9.13 EGFR EPHA7 ERBB2
18 positive regulation of MAP kinase activity GO:0043406 8.92 EGFR ERBB2 EZH2 SRC

Molecular functions related to Gallbladder Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.62 EGFR EPHA7 ERBB2 SRC
2 ubiquitin protein ligase binding GO:0031625 9.56 CCT2 EGFR SRC TSG101
3 ephrin receptor binding GO:0046875 9.37 EPHA7 SRC
4 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.16 EGFR ERBB2
5 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.13 EGFR EPHA7 ERBB2
6 protein tyrosine kinase activity GO:0004713 8.92 EGFR EPHA7 ERBB2 SRC

Sources for Gallbladder Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....